Free Trial

Illumina (ILMN) Stock Forecast & Price Target

Illumina logo
$84.98 +2.32 (+2.81%)
Closing price 04:00 PM Eastern
Extended Trading
$84.50 -0.48 (-0.56%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Illumina - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
9
Buy
10

Based on 20 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 1 has given a sell rating, 9 have given a hold rating, 9 have given a buy rating, and 1 has given a strong buy rating for ILMN.

Consensus Price Target

$128.84
51.61% Upside
According to the 20 analysts' twelve-month price targets for Illumina, the average price target is $128.84. The highest price target for ILMN is $200.00, while the lowest price target for ILMN is $77.00. The average price target represents a forecasted upside of 51.61% from the current price of $84.98.
Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

Sign Up

ILMN Analyst Ratings Over Time

TypeCurrent Forecast
6/9/24 to 6/9/25
1 Month Ago
5/10/24 to 5/10/25
3 Months Ago
3/11/24 to 3/11/25
1 Year Ago
6/10/23 to 6/9/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
Hold
9 Hold rating(s)
10 Hold rating(s)
10 Hold rating(s)
11 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$128.84$133.00$146.85$161.24
Forecasted Upside51.61% Upside75.55% Upside73.75% Upside41.81% Upside
Consensus Rating
Moderate Buy
Hold
Hold
Hold

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside51.61% Upside5,918.89% Upside13.46% Upside
News Sentiment Rating
Very Positive News

See Recent ILMN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/20/2025Stephens
4 of 5 stars
Mason Carrico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $105.00+26.58%
5/15/2025Piper Sandler
2 of 5 stars
David Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$190.00 ➝ $185.00+129.39%
5/12/2025Morgan Stanley
3 of 5 stars
Tejas Savant
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$136.00 ➝ $100.00+24.99%
5/12/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kyle Mikson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetHold ➝ Hold$92.00 ➝ $87.00+14.84%
5/9/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Julia Qin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$120.00 ➝ $85.00+12.20%
5/9/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Subbu Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$122.00 ➝ $114.00+48.17%
4/10/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderweight ➝ Underweight$100.00 ➝ $77.00+9.33%
4/8/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Conor McNamara
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$128.00 ➝ $112.00+51.28%
4/7/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$90.00 ➝ $85.00+18.37%
3/5/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Catherine Ramsey
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$127.00 ➝ $90.00+6.02%
2/28/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Gupta
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
2/28/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$100.00+12.40%
2/7/2025TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brennan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$177.00 ➝ $140.00+14.01%
11/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$133.00 ➝ $145.00-4.89%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$160.00 ➝ $200.00+38.91%
8/28/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$150.00+14.59%
8/16/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/16/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$120.00 ➝ $154.00+19.57%
8/15/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetSector Outperform ➝ Sector Outperform$176.00 ➝ $164.00+27.33%
6/11/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$195.00 ➝ $175.00+59.35%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$115.00+10.28%
3/20/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingPositive ➝ Mixed
12/15/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$175.00+48.76%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$140.00 ➝ $100.00-14.99%
10/12/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$200.00+49.91%
8/10/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$225.00 ➝ $200.00+8.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 12:08 AM ET.


Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, June 5, 2025. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina, Inc. recently reported earnings per share (EPS) of $0.97, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • The company has a positive return on equity of 13.37%, suggesting effective management and profitability relative to shareholder equity.
  • Illumina, Inc. has a consensus rating of "Moderate Buy" from analysts, indicating overall positive sentiment towards the stock.
  • Insider buying activity, such as the CFO acquiring shares, can signal confidence in the company's future prospects, which may encourage other investors.
  • The current stock price is around $80, which may present a buying opportunity for investors looking for value in the life sciences sector.

Illumina
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • The company experienced a year-over-year revenue decline of 1.4%, which could indicate challenges in maintaining growth.
  • Illumina, Inc. has a negative net margin of 27.95%, suggesting that the company is currently spending more than it earns, which could be a concern for profitability.
  • Recent price target reductions by analysts, including a drop to $77, may reflect a cautious outlook on the stock's future performance.
  • The stock has a price-to-earnings ratio of -10.46, indicating that the company is not currently profitable, which can be a red flag for potential investors.
  • Market volatility, as indicated by a beta of 1.35, suggests that the stock may experience larger price fluctuations compared to the overall market, which could pose risks for investors.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $128.84, with a high forecast of $200.00 and a low forecast of $77.00.

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There is currently 1 sell rating, 9 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ILMN shares.

According to analysts, Illumina's stock has a predicted upside of 51.61% based on their 12-month stock forecasts.

Illumina has been rated by research analysts at Barclays, Canaccord Genuity Group, Citigroup, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Royal Bank of Canada, and Stephens in the past 90 days.

Analysts like Illumina less than other "medical" companies. The consensus rating score for Illumina is 2.50 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ILMN compares to other companies.


This page (NASDAQ:ILMN) was last updated on 6/9/2025 by MarketBeat.com Staff
From Our Partners